Heyuan Biotechnology

Heyuan Biotechnology

Private
Tianjin, TianjinHealthcare & Life Scienceshttps://www.juventas.cn

Last Round

Series C

Jul 12, 2021

Total Funding Raised

$169.6M

Company Overview

Juventas Biology is a biotechnology company that develops immune cell therapies aimed at advancing treatment options for malignant hematological neoplasms like leukemia and lymphoma.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

CAR-T therapycell and gene therapyCGTCD19 CAR-TInaticabtagene Autoleucelcancer immunotherapyautologous cell therapyliving drughematologic malignanciesB-cell ALLbiopharmaceutical manufacturingGMP manufacturingsolid tumor therapyautoimmune disease therapyorphan drugCNCT19

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Heyuan Biotechnology Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Heyuan Biotechnology Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series CJul 12, 2021
Series BNov 19, 2020
Series A ExtensionJul 8, 2019
Series ADec 8, 2018

Key People

Founding team and executive leadership

James Wang

Chief Technology Officer (CTO)

Executive Team

Heyuan Biotechnology Investors

Notable investors and investment history

InvestorRounds
Emerging Technology PartnersSeries B
China International Capital CorporationSeries C
Dalton VentureSeries A Extension
Delian CapitalSeries C
Daotong InvestmentSeries A, Series A Extension, Series B, Series C
Danlu CapitalSeries C, Series A

Heyuan Biotechnology Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Heyuan Biotechnology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Heyuan Biotechnology's valuation, stock price, and market status.

Firmographic Details

HeadquartersTianjin, Tianjin
Employee Range32
Year Founded2018
Last FundingJul 12, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.